BRAF and neoplasm: Our BRAF-mutated models demonstrated the highest level of sensitivity to combined therapy of selumetinib and KRT-232 and greatest tumor reduction, especially in our PDX.008 model (which harbors an activating BRAF K601N mutation), despite introduction of a hiatus and re-challenging with treatment.